title: [Hodgkin lymphoma in Chile: experience of the national adult cancer program].
abstract: BACKGROUND
  Hodgkin lymphoma is a highly curable disease.
  
  
  OBJECTIVE
  To evaluate the clinical characteristics and the treatment results of Hodgkin lymphoma patients of the National Cancer Program in Chile.
  
  
  METHODS
  Prospective assessment of 682 patients treated in 18 adult cancer centers. Progression free survival (PFS) and overall survival (OS) were calculated. Median follow up was 127, 95, 87, 72 and 50 months for C-MOPP, radiotherapy (RT), C-MOPP/ABV, NOVP and ABVD, respectively.
  
  
  RESULTS
  Median age was 37 years (15-84). Nodular sclerosis and mixed cellularity were equally expressed. Advanced stages (III & IV) were present at diagnosis in 61% of cases. Age over 40 was an adverse prognostic factor (p<0.001). The rate of PFS at 5 and 10 years for early stages was 73% and 66% with RT, 80% and 74% with C-MOPP+RT, 73% and 71% with C-MOPP/ABV, 59% and 59% with NOVP+RT, and 81% with ABVD+RT, at 5 years, being significantly lower for NOVP (p=0.02). The rate of OS at 5 and 10 years for advanced stages was 82% and 70% with RT, 82% and 76% with C-MOPP+RT, 82% and 80% with C-MOPP/ABV, 68% and 60% with NOVP, and 85% with ABVD at 5 years, also significantly lower for NOVP (p=0.04). For advanced stages, the rate of PFS at 5 and 10 years was 49% and 43% with C-MOPP, 69% and 62% with C-MOPP/ABVD or C-MOPP/ABV, and 71% at 5 years with ABVD, significantly lower for C-MOPP (p=0.01). The rate of OS at 5 and 10 years was 52% and 46% with C-MOPP, 70% and 63% with C-MOPP/ABVD or C-MOPP/ABV and 76% with ABVD at 5 years, significantly lower for C-MOPP (p=0.0002).
  
  
  CONCLUSIONS
  Age over 40 years was an adverse prognostic factor. C-MOPP/ABVD, C-MOPP/ABV and ABVD had comparable results and reached a high tumor control and overall survival in both early and advanced stages.
authors.affiliation: Hospital del Salvador, Santiago, Chile. mecabrera@vtr.net
authors.forename: M Elena
authors.initials: ME
authors.lastname: Cabrera
authors.forename: Hernán
authors.initials: H
authors.lastname: García
authors.forename: Vivian
authors.initials: V
authors.lastname: Lois
authors.forename: Alvaro
authors.initials: A
authors.lastname: León
authors.forename: Karina
authors.initials: K
authors.lastname: Peña
authors.forename: Alberto
authors.initials: A
authors.lastname: Rossle
authors.forename: Berta
authors.initials: B
authors.lastname: Cerda
authors.forename: Hernán
authors.initials: H
authors.lastname: Rojas
authors.forename: Pedro
authors.initials: P
authors.lastname: Meneses
authors.forename: Carlos
authors.initials: C
authors.lastname: Merino
authors.forename: Augusto
authors.initials: A
authors.lastname: Aspillaga
authors.forename: Cecilia
authors.initials: C
authors.lastname: Vittini de
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Oliva
authors.forename: Cecilia
authors.initials: C
authors.lastname: Hales
authors.forename: Janet
authors.initials: J
authors.lastname: Rosas
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D016009:Chi-Square Distribution; D002677:Chile; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009313:National Health Programs; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011446:Prospective Studies; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D008942:Mitoxantrone; D011241:Prednisone